Kishore Kamal
University of Illinois College of Medicine, Peoria, Ill., USA.
Case Rep Ophthalmol. 2016 Sep 26;7(3):162-171. doi: 10.1159/000449122. eCollection 2016 Sep-Dec.
To report the 1-year follow-up results of intravitreal aflibercept injection (IAI) for the management of complications of retinal artery macroaneurysms (RAM).
A retrospective, noncomparative, interventional case series of 4 eyes of 4 patients (all female, aged 68-91 years, 3 treatment naive) treated with IAI 2 mg for complications of RAM [macular edema (ME) 2, submacular hemorrhage (SMH) 1, and vitreous hemorrhage (VH) 1] was conducted. Baseline parameters consisted of complete ocular examination, medical history, best-corrected Snellen VA, fundus photography, IVFA and SD OCT, unless precluded by VH (1). All patients completed ≥1 year follow-up.
Baseline VA was hand motions in the eye with SMH (31 mm area and 1,478 μm thickness); 20/40 and 20/100 with ME (CST 390 and 337 μm, respectively), and 20/200 in the eye with VH. At 1 month, both patients with ME showed resolution of ME with CST <300 μm with improvement in VA which was maintained through 1 year. VH resolved in one eye at 1 month with no recurrence after 1 year. The eye with SMH developed macular scar and had counting fingers vision at 1 year. Thrombosis of RAM was noted in all eyes and hairpin-like remodeling of artery in one. No eye required repeat injection or laser.
ME and VH from RAM were effectively treated with IAI. However, the eye with thick SMH had poor visual outcome despite thrombosis of RAM. Single IAI provided effective therapy for complications of RAM with excellent anatomical and visual results in each eye, except one with thick SMH, and merits further study.
报告玻璃体内注射阿柏西普(IAI)治疗视网膜动脉大动脉瘤(RAM)并发症的1年随访结果。
对4例患者的4只眼(均为女性,年龄68 - 91岁,3例初治)进行回顾性、非对照、介入性病例系列研究,采用2mg IAI治疗RAM并发症[黄斑水肿(ME)2例、黄斑下出血(SMH)1例、玻璃体积血(VH)1例]。基线参数包括完整的眼部检查、病史、最佳矫正视力、眼底照相、吲哚菁绿血管造影(IVFA)和频域光学相干断层扫描(SD OCT),除非因VH(1例)而无法进行。所有患者均完成了≥1年的随访。
基线视力方面,SMH眼为手动视力(面积31mm,厚度1478μm);ME患者分别为20/40和20/100(中央视网膜厚度分别为390μm和337μm),VH眼为20/200。1个月时,2例ME患者的ME均消退,中央视网膜厚度<300μm,视力改善,并维持至1年。1例VH患者在1个月时玻璃体积血消退,1年后无复发。SMH眼在1年时形成黄斑瘢痕,视力为指数。所有眼中均观察到RAM血栓形成,1眼中动脉呈发夹样重塑。无一例眼需要重复注射或激光治疗。
IAI有效治疗了RAM引起的ME和VH。然而,尽管RAM发生血栓形成,但SMH较厚的眼视力预后较差。单次IAI为RAM并发症提供了有效的治疗,除1例SMH较厚的眼外,每只眼均获得了良好的解剖和视觉效果,值得进一步研究。